List of Excipients in Branded Drug REDITREX

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Cumberland Pharmaceuticals Inc	REDITREX	methotrexate	66220-807	SODIUM CHLORIDE
Cumberland Pharmaceuticals Inc	REDITREX	methotrexate	66220-807	SODIUM HYDROXIDE
Cumberland Pharmaceuticals Inc	REDITREX	methotrexate	66220-807	WATER

REDITREX Excipient Strategy and Commercial Opportunities

Last updated: September 29, 2026

REDITREX is a preservative-free, single-dose subcutaneous methotrexate injection supplied in prefilled syringes. Its formulation uses a minimal excipient system: sodium chloride for tonicity, hydrochloric acid and sodium hydroxide for pH adjustment, and water for injection. The commercial value is therefore concentrated in dose flexibility, injectable convenience, packaging, manufacturing reliability, and payer access rather than in a complex excipient platform.[1]

What is REDITREX and how is it formulated?

REDITREX is methotrexate injection for subcutaneous use. The FDA-approved product is indicated for rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, and severe psoriasis in patients who do not respond adequately to other therapies or cannot tolerate them.[1]

REDITREX formulation profile

Attribute	REDITREX position
Active ingredient	Methotrexate
Dosage form	Injectable solution
Route	Subcutaneous
Presentation	Single-dose prefilled syringe
Labeled strengths	7.5, 10, 15, 17.5, 20, 22.5 and 25 mg per 0.4 mL
Preservative	None listed
Tonicity agent	Sodium chloride
pH adjustment	Hydrochloric acid and sodium hydroxide
Vehicle	Water for injection
Primary use	Chronic outpatient treatment
FDA approval	REDITREX NDA approved in 2019
Key commercial comparator	Rasuvo, Otrexup, generic methotrexate injection and oral methotrexate

The formulation is aqueous and does not rely on a proprietary polymer, liposome, depot system, surfactant, antioxidant or antimicrobial preservative. The label identifies sodium chloride, hydrochloric acid, sodium hydroxide and water for injection as inactive ingredients.[1]

Why does REDITREX use a low-excipient formulation?

A low-excipient formulation reduces formulation complexity and limits the number of potential sources of injection-site reactions, intolerance and extractables or leachables concerns. This is relevant for a chronic therapy administered outside a hospital.

The excipient strategy supports four product objectives:

1. Parenteral tolerability. The formulation avoids preservatives and unnecessary solubilizers.
2. Chemical simplicity. Methotrexate is delivered as an aqueous solution rather than a suspension or complex delivery system.
3. Manufacturing reproducibility. A short excipient list simplifies weighing, mixing, filtration, filling and release testing.
4. Device compatibility. A simple aqueous solution is suitable for a prefilled syringe, provided container closure, needle, lubricant and syringe materials are compatible.

The limited excipient burden does not by itself create a strong exclusivity position. Generic methotrexate manufacturers can generally use alternative pharmaceutically acceptable excipients if their products meet applicable quality, safety and bioequivalence requirements.

What excipients are protected by the REDITREX formulation?

The listed excipients are established pharmaceutical ingredients and are unlikely to provide meaningful standalone patent protection. Sodium chloride, water for injection and pH adjusters are commoditized materials. A competitor could use the same excipients without infringing a patent merely because they appear in the REDITREX label.

Any defensible formulation or product IP would more likely relate to:

• Specific concentration and pH ranges.
• Methotrexate stability in the final container.
• Control of degradation products.
• Syringe component compatibility.
• Needle geometry and injection performance.
• Fill volume and dose-concentration architecture.
• Manufacturing controls for sterile filtration and aseptic filling.
• Packaging configurations that preserve stability.
• Human-factors design for self-administration.

The commercial distinction is therefore product-system based. The excipient list is part of that system, but it is not likely to be the main source of patent value.

What formulation patents protect REDITREX?

Publicly available FDA labeling identifies the composition but does not establish that the excipient combination itself has broad, standalone patent protection. Methotrexate is an old active pharmaceutical ingredient, so basic composition-of-matter exclusivity is unavailable.

The relevant IP categories are likely to be narrower:

IP category	Relevance to REDITREX	Expected strength
Methotrexate API patent	Expired or unavailable for this product	Very low
Basic aqueous methotrexate solution	Difficult to protect broadly	Low
Specific concentration and pH	Potentially protectable if technically distinctive	Low to moderate
Stability and impurity control	Potential value in formulation and process claims	Moderate
Prefilled syringe configuration	Potential device and combination-product value	Moderate
Injection device ergonomics	Potential design or utility protection	Moderate
Manufacturing process	Potentially confidential or patentable	Moderate
Brand and trade dress	Commercial protection, not formulation exclusivity	Moderate

A patent-strength assessment requires claim-by-claim review of granted patents, pending applications, terminal disclaimers, prosecution history and Orange Book listings. The active ingredient itself does not create a meaningful barrier to generic entry.

When does REDITREX lose exclusivity?

REDITREX received FDA approval in 2019. Because methotrexate was already a well-established active ingredient, REDITREX did not receive new-chemical-entity exclusivity based on methotrexate itself.[1,2]

The principal regulatory barriers are product-specific patents, any applicable clinical-investigation exclusivity, labeling restrictions and the requirements for an abbreviated new drug application. FDA approval of a generic injectable product would require demonstration of pharmaceutical equivalence and bioequivalence or another accepted basis for approval, together with adequate chemistry, manufacturing and controls data.[2]

REDITREX exclusivity timeline

Milestone	Date or status
Methotrexate established active ingredient	Long before REDITREX approval
REDITREX FDA approval	2019
New chemical entity exclusivity	Not applicable to methotrexate
Five-year NCE period	Not applicable
Product-specific patent term	Depends on listed or asserted patents
Generic pathway	ANDA or other applicable abbreviated pathway
Biosimilar pathway	Not applicable

The practical loss-of-exclusivity risk is different from that of a new molecular entity. Generic developers do not need to reproduce REDITREX’s exact excipient system if they can demonstrate equivalent performance under FDA requirements.

What is the Orange Book status of REDITREX?

The Orange Book is the principal FDA source for approved drug products, therapeutic equivalence evaluations and listed patent information.[2] For REDITREX, the commercially relevant question is whether the NDA has current, unexpired patent listings that could trigger a Paragraph IV certification and potential litigation.

The product’s patent exposure should be assessed across:

• NDA listings for the prefilled syringe product.
• Drug substance and drug product patents.
• Device-related patent listings, where eligible.
• Patent expiration dates and pediatric extensions.
• Whether any listed patent covers the approved labeling.
• Whether a generic applicant could make a section viii statement for an indication or use.

A Paragraph IV certification would allege that a listed patent is invalid, unenforceable or not infringed. The NDA holder could respond with patent litigation, generally seeking a 30-month stay of FDA approval under the Hatch-Waxman framework, subject to statutory conditions.[3]

No assumption should be made that a formulation patent prevents generic entry. A patent covering a narrow device configuration may be avoided through a redesigned syringe, while a method-of-use patent may be avoided through a section viii labeling carve-out.

Which companies compete with REDITREX?

REDITREX competes in several segments rather than against a single product.

Product or category	Manufacturer or supplier	Delivery format	Commercial relevance
REDITREX	Teva Pharmaceuticals	Prefilled syringe	Broad labeled dose range and self-injection positioning
Rasuvo	Medac Pharma	Autoinjector	Device-oriented alternative
Otrexup	Antares Pharma, historically commercialized through partners	Autoinjector	Competes on ease of administration
Generic methotrexate injection	Multiple manufacturers	Vials or other injectable formats	Lower acquisition cost, less convenience
Oral methotrexate tablets	Multiple manufacturers	Tablets	Lowest-cost alternative for suitable patients
Methotrexate oral solution	Various suppliers	Oral liquid	Alternative for patients with swallowing or dosing issues

Rasuvo and Otrexup compete through autoinjector convenience. REDITREX competes through a prefilled syringe, dose availability and potentially broader distribution. Vial-based methotrexate products compete primarily on price and institutional purchasing.

How does REDITREX compare with Rasuvo and Otrexup?

The principal difference is the delivery device, not the pharmacology.

Attribute	REDITREX	Rasuvo	Otrexup
Active ingredient	Methotrexate	Methotrexate	Methotrexate
Route	Subcutaneous	Subcutaneous	Subcutaneous
Device	Prefilled syringe	Autoinjector	Autoinjector
Dose architecture	Multiple fixed doses	Multiple fixed doses	Multiple fixed doses
Preservative-free positioning	Yes, according to product labeling	Product-specific labeling	Product-specific labeling
Main differentiation	Ready-to-use syringe and dose selection	Automated injection	Automated injection
Primary risk	Generic and device substitution	Device cost and coverage	Device cost and coverage

Autoinjectors may have an advantage for patients with needle fear, limited dexterity or preference for concealed-needle administration. Prefilled syringes may offer lower device complexity, easier visual confirmation of the dose and potentially lower manufacturing cost.

What commercial opportunities exist for REDITREX excipient strategy?

1. Preservative-free chronic injection positioning

A preservative-free formulation can support use in chronic outpatient treatment, particularly when patients or prescribers want to limit unnecessary excipients. This positioning is clinically relevant but should not imply superior efficacy or universal tolerability without comparative evidence.

2. Dose-range optimization

REDITREX covers a broad set of weekly doses. Dose granularity can reduce the need for syringe manipulation or volume calculations. This is commercially useful in rheumatoid arthritis, juvenile idiopathic arthritis and psoriasis, where dose titration is common.

3. Device and packaging differentiation

The highest-value product opportunities are likely to involve:

• Smaller-gauge or less painful needles.
• Improved plunger force.
• Reduced injection volume.
• Clear dose visibility.
• Better labeling for weekly administration.
• Tamper-evident and child-resistant packaging.
• Integrated sharps-disposal solutions.
• Packaging designed for refrigerated distribution and home storage.

These improvements can support premium positioning even when the formulation is simple.

4. Stability and supply-chain improvements

A formulation with a short excipient list may be easier to manufacture, but commercial performance still depends on sterile fill-finish capacity, syringe availability and cold-chain execution. Opportunities include:

• Dual sourcing of sodium chloride and packaging components.
• Regional fill-finish capacity.
• Improved cold-chain packaging.
• Longer validated shelf life.
• Reduced syringe breakage and shipping damage.
• Automated visual inspection for particulates and container defects.

A supplier that can provide reliable prefilled-syringe capacity may capture value even without owning a differentiated excipient technology.

5. Patient-support and adherence programs

Methotrexate is commonly administered weekly, creating a risk of dosing errors. Commercial programs can focus on:

• Weekly-dose reminders.
• Caregiver training.
• Injection education.
• Disposal support.
• Switching from oral to subcutaneous treatment.
• Specialty-pharmacy coordination.
• Reimbursement support.

The labeling carries a boxed warning concerning serious toxicities and the risk of daily rather than weekly administration.[1] Packaging and patient-support materials therefore have direct risk-management value.

What generic entry risks exist for REDITREX?

Generic entry risk is substantial because methotrexate is an established generic active ingredient. The principal barriers are product development and device execution rather than API discovery.

Generic launch scenarios

Scenario 1: Vial-based generic entry.
A low-cost generic methotrexate injection could compete for institutional and price-sensitive prescriptions without duplicating the prefilled-syringe format.

Scenario 2: Prefilled-syringe entry.
A competitor could target REDITREX directly with a ready-to-use syringe, using the same or a different excipient system.

Scenario 3: Autoinjector substitution.
An autoinjector could capture patients who prioritize ease of use over syringe familiarity.

Scenario 4: Oral substitution.
Patients who can tolerate oral therapy may move to lower-cost tablets or oral solution, limiting the addressable market for injectable products.

Scenario 5: Specialty-pharmacy contracting.
Payers may favor the product with the lowest net cost, reducing the value of modest device or excipient differentiation.

Is there biosimilar risk for REDITREX?

No. REDITREX contains methotrexate, a small-molecule drug. Biosimilar regulation under the Public Health Service Act applies to biological products, not conventional methotrexate injections.[4]

The relevant competitive threats are generic methotrexate products, alternative injection devices, oral methotrexate and other disease-modifying antirheumatic drugs. Biologic therapies for rheumatoid arthritis and psoriasis create therapeutic competition, but they are not biosimilar substitutes for REDITREX.

What FDA regulatory issues affect REDITREX commercialization?

The key FDA issues are:

• Sterility assurance for the injectable product.
• Container-closure integrity.
• Particulate and visible inspection controls.
• Methotrexate assay and degradation-product limits.
• Syringe and needle compatibility.
• Human-factors validation for self-administration.
• Accurate weekly dosing instructions.
• Pregnancy and reproductive-toxicity warnings.
• Safe handling and disposal.
• Labeling for the approved indications.

Because REDITREX is a drug-device combination product, the formulation and delivery system must perform together. A change to syringe materials, needle dimensions, lubrication, fill volume or packaging may require regulatory assessment even if the excipient composition remains unchanged.

How strong is the REDITREX patent estate?

The estate is likely stronger around product presentation and device execution than around excipients or methotrexate chemistry. The active ingredient is old, the listed excipients are conventional, and multiple competing methotrexate injection products establish a crowded technical field.

A practical strength ranking is:

1. Brand and product recognition: moderate.
2. Prefilled-syringe configuration: moderate, subject to design-around risk.
3. Manufacturing know-how: moderate if process parameters are difficult to reproduce.
4. Stability and impurity controls: moderate if supported by narrow technical claims.
5. Excipient composition: low.
6. Methotrexate molecule: negligible for modern exclusivity purposes.

Key Takeaways

• REDITREX uses a simple, preservative-free aqueous formulation with sodium chloride, pH adjusters and water for injection.
• The excipient system supports tolerability, manufacturability and prefilled-syringe compatibility but is unlikely to create broad standalone exclusivity.
• Commercial differentiation is concentrated in dose flexibility, device usability, packaging, patient support and payer contracting.
• Methotrexate is not eligible for biosimilar competition; generic and device-based competition are the primary risks.
• REDITREX’s strongest potential IP positions are likely to involve the syringe, stability controls, manufacturing process and combination-product design.
• Generic entry could occur through vials, prefilled syringes, autoinjectors or oral methotrexate, depending on approval pathway and market economics.
• The weekly dosing schedule and serious toxicity warnings make packaging, labeling and adherence support important commercial assets.

FAQs

Can a competitor copy REDITREX’s excipients?

A competitor can generally use the same conventional excipients if its product satisfies FDA quality, safety, stability and equivalence requirements. Patent protection, if any, would depend on narrow claims covering concentrations, pH, stability, manufacturing or device integration.

Is REDITREX preservative-free?

Yes. The FDA labeling identifies sodium chloride, hydrochloric acid, sodium hydroxide and water for injection, with no antimicrobial preservative listed.[1]

Does REDITREX have a unique methotrexate concentration?

REDITREX is supplied in multiple fixed-dose strengths in a 0.4 mL prefilled-syringe format. The dose architecture, rather than the methotrexate molecule, is the relevant product differentiator.

Can an oral methotrexate generic replace REDITREX?

For clinically suitable patients, oral methotrexate can compete with injectable methotrexate. The choice depends on efficacy, gastrointestinal tolerance, adherence, patient preference, disease severity and prescriber judgment.

What is the most valuable commercial improvement to REDITREX?

A lower-friction injection experience is likely to have the greatest commercial value. Improvements to needle comfort, device handling, dose visibility, weekly-dose reminders, packaging and reimbursement access can differentiate the product more effectively than adding new excipients.

References

1. U.S. Food and Drug Administration. (2019). REDITREX (methotrexate injection) prescribing information. Teva Pharmaceuticals USA, Inc.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (2024). Hatch-Waxman amendments and abbreviated new drug applications. https://www.fda.gov/drugs

4. U.S. Food and Drug Administration. (2024). Biosimilar and interchangeable biosimilar products. https://www.fda.gov/drugs/therapeutic-biologics-applications-bla/biosimilars.